<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02089399</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ1351001</org_study_id>
    <nct_id>NCT02089399</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Drug Interaction Study Between Amlodipine,Olmesartan and Rosuvastatin in Healthy Adult Volunteers</brief_title>
  <official_title>An Open Label, Randomized, 2-Sequence, Multiple-Dose, Cross-Over Study to Investigate the Drug-Drug Interaction of Sevikar and Crestor in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics profile and drug-drug
      interaction between amlodipine, olmesartan and rosuvastatin in healthy adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCtau</measure>
    <time_frame>Multiple blood sample will be collected for 24 hours after last dosing in each of the treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Css,max</measure>
    <time_frame>Multiple blood sample will be collected for 24 hours after last dosing in each of the treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tss,max</measure>
    <time_frame>Multiple blood sample will be collected for 24 hours after last dosing in each of the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Css,min</measure>
    <time_frame>Multiple blood sample will be collected for 24 hours after last dosing in each of the treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment AB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-&gt;S+C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevikar(amlodipne/olmesartan)</intervention_name>
    <description>Treatment AB</description>
    <arm_group_label>Treatment AB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crestor(Rosuvastatin)</intervention_name>
    <description>Treatment AB/Treatment C</description>
    <arm_group_label>Treatment AB</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects aged 19 - 55 years

          -  A body mass index in the range 19 - 27 kg/m2

          -  Willingness to participate during the entire study period

          -  Written informed consent after being fully informed about the study procedures

        Exclusion Criteria:

          -  Any past medical history of hepatic, renal, gastrointestinal, respiratory, endocrine,
             psychiatric, neurologic, haemato-oncologic or cardiovascular disease

          -  History of clinically significant drug hypersensitivity

          -  Use of medication within 7 days before the first dose

          -  Heavy drinker (&gt;140 g/week)

          -  Whole blood donation during 60 days before the study

          -  Judged not eligible for study participation by investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2014</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

